Onkologie. 2024:18(Suppl.C):6-12 | DOI: 10.36290/xon.2024.044
Enfortumab vedotin in the treatment of generalized urothelial carcinoma of the renal pelvis and ureter
- Onkologická klinika FNKV, Praha
Antibody-drug conjugates are gradually being incorporated into recommended treatment protocols for various cancer diagnoses, primarily breast cancer and haematological malignancies. However, in patients with generalized urothelial carcinoma who have been pretreated with chemotherapy and immunotherapy, a drug of this type - enfortumab vedotin - is also indicated and now reimbursed in the Czech Republic. Our case report documents the potential benefit of this drug in the treatment of urothelial carcinoma of the renal pelvis and ureter.
Keywords: generalized urothelial carcinoma, antibody-drug conjugates, enfortumab vedotin.
Accepted: September 12, 2024; Published: October 2, 2024 Show citation
References
- Hamid A, Ridwan FR, Parikesit D, et al. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 2020;20(1):158.
Go to original source... 
Go to PubMed... - Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49-64. Go to original source... Go to PubMed...
- National Cancer Institute. Cancer Stat Facts: Bladder Cancer 2021 [cited 4. 3. 2024]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html.
- Knott C, Kearney M, Mahmoudpour H, et al. Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England. Ann Oncol. 2022;33:1750P. Go to original source...
- Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States. Bladder Cancer. 2018;4:227-238. Go to original source... Go to PubMed...
- Richters A, Mehra N, Meijer RP, et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25:100266. Go to original source... Go to PubMed...
- von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-4608. Go to original source... Go to PubMed...
- Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404-423. Go to original source... Go to PubMed...
- Powles T, Park SH, Caserta C, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. J Clin Oncol. 2023;41(19):3486-3492. Go to original source... Go to PubMed...
- Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. Go to original source... Go to PubMed...
- Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. Go to original source... Go to PubMed...